Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt No Debt
RIGL's Cash-to-Debt is ranked higher than
99% of the 799 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.09 vs. RIGL: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
RIGL' s Cash-to-Debt Range Over the Past 10 Years
Min: 4.48  Med: 68.79 Max: No Debt
Current: No Debt
Equity-to-Asset 0.83
RIGL's Equity-to-Asset is ranked higher than
62% of the 734 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. RIGL: 0.83 )
Ranked among companies with meaningful Equity-to-Asset only.
RIGL' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.43  Med: 0.75 Max: 0.94
Current: 0.83
0.43
0.94
Interest Coverage No Debt
RIGL's Interest Coverage is ranked higher than
99% of the 635 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 105.95 vs. RIGL: No Debt )
Ranked among companies with meaningful Interest Coverage only.
RIGL' s Interest Coverage Range Over the Past 10 Years
Min: 388.1  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 2
Altman Z-Score: -5.71
Beneish M-Score: -3.67
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % -361.05
RIGL's Operating Margin % is ranked lower than
91% of the 744 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.42 vs. RIGL: -361.05 )
Ranked among companies with meaningful Operating Margin % only.
RIGL' s Operating Margin % Range Over the Past 10 Years
Min: -14938.27  Med: -1106.05 Max: 28.25
Current: -361.05
-14938.27
28.25
Net Margin % -354.13
RIGL's Net Margin % is ranked lower than
91% of the 745 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.16 vs. RIGL: -354.13 )
Ranked among companies with meaningful Net Margin % only.
RIGL' s Net Margin % Range Over the Past 10 Years
Min: -14872.93  Med: -1101.92 Max: 30.31
Current: -354.13
-14872.93
30.31
ROE % -94.67
RIGL's ROE % is ranked lower than
92% of the 768 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.86 vs. RIGL: -94.67 )
Ranked among companies with meaningful ROE % only.
RIGL' s ROE % Range Over the Past 10 Years
Min: -142.04  Med: -50.45 Max: 27.46
Current: -94.67
-142.04
27.46
ROA % -70.49
RIGL's ROA % is ranked lower than
92% of the 799 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.49 vs. RIGL: -70.49 )
Ranked among companies with meaningful ROA % only.
RIGL' s ROA % Range Over the Past 10 Years
Min: -101.94  Med: -43.28 Max: 23.14
Current: -70.49
-101.94
23.14
ROC (Joel Greenblatt) % -5092.81
RIGL's ROC (Joel Greenblatt) % is ranked lower than
95% of the 785 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.40 vs. RIGL: -5092.81 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
RIGL' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -5092.81  Med: -2565.59 Max: 1113
Current: -5092.81
-5092.81
1113
3-Year Revenue Growth Rate 38.10
RIGL's 3-Year Revenue Growth Rate is ranked higher than
93% of the 607 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.70 vs. RIGL: 38.10 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
RIGL' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -37.9 Max: 121.7
Current: 38.1
0
121.7
3-Year EBITDA Growth Rate -9.80
RIGL's 3-Year EBITDA Growth Rate is ranked lower than
78% of the 583 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.40 vs. RIGL: -9.80 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
RIGL' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -47  Med: -21.7 Max: 23.2
Current: -9.8
-47
23.2
3-Year EPS without NRI Growth Rate -10.60
RIGL's 3-Year EPS without NRI Growth Rate is ranked lower than
72% of the 551 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.00 vs. RIGL: -10.60 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
RIGL' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -56.5  Med: -21.5 Max: 21.8
Current: -10.6
-56.5
21.8
GuruFocus has detected 3 Warning Signs with Rigel Pharmaceuticals Inc $RIGL.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» RIGL's 30-Y Financials

Financials (Next Earnings Date: 2017-07-25 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

RIGL Guru Trades in Q2 2016

Jim Simons 792,600 sh (+19.95%)
John Paulson 999,700 sh (unchged)
Paul Tudor Jones 29,251 sh (unchged)
» More
Q3 2016

RIGL Guru Trades in Q3 2016

Paul Tudor Jones 42,241 sh (+44.41%)
John Paulson 805,000 sh (-19.48%)
Jim Simons 629,800 sh (-20.54%)
» More
Q4 2016

RIGL Guru Trades in Q4 2016

Paul Tudor Jones Sold Out
Jim Simons Sold Out
John Paulson 387,697 sh (-51.84%)
» More
Q1 2017

RIGL Guru Trades in Q1 2017

John Paulson 550,000 sh (+41.86%)
» More
» Details

Insider Trades

Latest Guru Trades with RIGL

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412    SIC: 2834
Compare:NAS:TTPH, NAS:AQXP, NAS:TOCA, NAS:COLL, NAS:ZYNE, NAS:SNDX, NAS:ADMS, NAS:LBIO, OTCPK:OGRMF, OTCPK:CURR, NAS:NEOS, NAS:DRRX, NAS:CPRX, NAS:STDY, NAS:KPTI, OTCPK:ELTP, OTCPK:CMMDF, NAS:SMMT, NAS:ACET, NAS:MSLI » details
Traded in other countries:RI2A.Germany,
Headquarter Location:USA
Rigel Pharmaceuticals Inc is a clinical-stage biotechnology company. It discovers and develops novel, small-molecule drugs for the treatment of inflammatory/autoimmune diseases, as well as for certain cancers and metabolic diseases.

Rigel Pharmaceuticals develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken over all responsibility to develop and market the drug and will pay Rigel royalties and milestone payments.

Ratios

vs
industry
vs
history
PB Ratio 3.47
RIGL's PB Ratio is ranked lower than
77% of the 770 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.03 vs. RIGL: 3.47 )
Ranked among companies with meaningful PB Ratio only.
RIGL' s PB Ratio Range Over the Past 10 Years
Min: 1.02  Med: 2.68 Max: 10.47
Current: 3.47
1.02
10.47
PS Ratio 12.32
RIGL's PS Ratio is ranked lower than
86% of the 721 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.90 vs. RIGL: 12.32 )
Ranked among companies with meaningful PS Ratio only.
RIGL' s PS Ratio Range Over the Past 10 Years
Min: 2.8  Med: 29.04 Max: 699.29
Current: 12.32
2.8
699.29
Current Ratio 5.77
RIGL's Current Ratio is ranked higher than
63% of the 700 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.55 vs. RIGL: 5.77 )
Ranked among companies with meaningful Current Ratio only.
RIGL' s Current Ratio Range Over the Past 10 Years
Min: 1.84  Med: 6.9 Max: 36.3
Current: 5.77
1.84
36.3
Quick Ratio 5.77
RIGL's Quick Ratio is ranked higher than
70% of the 699 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.85 vs. RIGL: 5.77 )
Ranked among companies with meaningful Quick Ratio only.
RIGL' s Quick Ratio Range Over the Past 10 Years
Min: 1.84  Med: 6.9 Max: 36.3
Current: 5.77
1.84
36.3

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -4.30
RIGL's 3-Year Average Share Buyback Ratio is ranked higher than
50% of the 442 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.30 vs. RIGL: -4.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
RIGL' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -153.2  Med: -18.8 Max: -1.3
Current: -4.3
-153.2
-1.3

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 3.62
RIGL's Price-to-Net-Cash is ranked higher than
66% of the 206 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 12.25 vs. RIGL: 3.62 )
Ranked among companies with meaningful Price-to-Net-Cash only.
RIGL' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 1.2  Med: 3.55 Max: 15.44
Current: 3.62
1.2
15.44
Price-to-Net-Current-Asset-Value 3.57
RIGL's Price-to-Net-Current-Asset-Value is ranked higher than
57% of the 443 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.16 vs. RIGL: 3.57 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
RIGL' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.2  Med: 3.27 Max: 13.37
Current: 3.57
1.2
13.37
Price-to-Tangible-Book 3.46
RIGL's Price-to-Tangible-Book is ranked lower than
66% of the 705 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.61 vs. RIGL: 3.46 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
RIGL' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.16  Med: 3 Max: 11.62
Current: 3.46
1.16
11.62
Price-to-Median-PS-Value 0.42
RIGL's Price-to-Median-PS-Value is ranked higher than
90% of the 645 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.13 vs. RIGL: 0.42 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
RIGL' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.05  Med: 0.58 Max: 23.2
Current: 0.42
0.05
23.2
Earnings Yield (Greenblatt) % -35.21
RIGL's Earnings Yield (Greenblatt) % is ranked lower than
91% of the 1046 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.36 vs. RIGL: -35.21 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
RIGL' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -35.21  Med: 15.5 Max: 6128.3
Current: -35.21
-35.21
6128.3

More Statistics

Revenue (TTM) (Mil) $18.94
EPS (TTM) $ -0.67
Beta1.21
Short Percentage of Float3.34%
52-Week Range $1.94 - 4.38
Shares Outstanding (Mil)122.43

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 28 64 56
EPS ($) -0.33 -0.11 -0.20
EPS without NRI ($) -0.33 -0.11 -0.20
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for RIGL

Headlines

Articles On GuruFocus.com
Rigel Announces First Quarter 2017 Financial Results and Provides Company Update May 02 2017 
Rigel Announces Tavalisse™ as Proprietary Name for Fostamatinib in the United States Apr 27 2017 
Rigel Announces Conference Call and Webcast to Report First Quarter 2017 Financial Results Apr 25 2017 
Rigel Submits New Drug Application to FDA for Fostamatinib in Chronic ITP Apr 17 2017 
Biocept (BIOC) Soars on Liquid Biopsy Appreciation, Rigel Pharmaceuticals (RIGL) Mega-deal with Bris Feb 23 2015 
Rigel Pharmaceuticals Inc. Reports Operating Results (10-K) Mar 01 2011 

More From Other Websites
ETFs with exposure to Rigel Pharmaceuticals, Inc. : May 16, 2017 May 16 2017
3 Biotech Stocks I'd Buy Right Now May 15 2017
Edited Transcript of RIGL earnings conference call or presentation 2-May-17 9:00pm GMT May 10 2017
Rigel Pharmaceuticals, Inc. :RIGL-US: Earnings Analysis: Q1, 2017 By the Numbers : May 4, 2017 May 04 2017
Rigel Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : RIGL-US : May... May 03 2017
Rigel reports 1Q loss May 02 2017
Rigel Announces First Quarter 2017 Financial Results and Provides Company Update May 02 2017
Investor Network: Rigel Pharmaceuticals, Inc. to Host Earnings Call May 02 2017
Rigel Announces Tavalisse™ as Proprietary Name for Fostamatinib in the United States Apr 27 2017
Rigel Announces Conference Call and Webcast to Report First Quarter 2017 Financial Results Apr 25 2017
Rigel Pharmaceuticals Files NDA for Thrombocytopenia Drug Apr 18 2017
Rigel Submits New Drug Application to FDA for Fostamatinib in Chronic ITP Apr 17 2017
5 Top Breakout Stocks to Boost Your Portfolio Mar 31 2017
Increased Earnings Estimates Seen for Rigel (RIGL): Can It Move Higher? Mar 27 2017
After Years of Stagnation, Are Shares of Rigel Pharmaceuticals About to Take off Into the... Mar 24 2017
Will Rigel Pharmaceuticals (RIGL) Continue to Surge Higher? Mar 24 2017
3 Beaten-Up Biotech Stocks: Are They Bargains? Mar 21 2017
3 Stocks That Are Ridiculously Cheap Right Now Mar 20 2017
5 Cheap Breakout Stocks for Superb Returns Mar 16 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)